These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35983810)

  • 21. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.
    Downes MR; Liu KN; Yu Y; Lajkosz K; Kroon LJ; Hollemans E; Fleshner N; Finelli A; van Leenders GJLH; Iczkowski KA; van der Kwast TH
    Clin Genitourin Cancer; 2024 Feb; 22(1):47-55. PubMed ID: 37558528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
    Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
    Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.
    Wang Y; Teramoto Y; Miyamoto H
    Hum Pathol; 2023 Aug; 138():112-120. PubMed ID: 37364826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
    Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
    Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based study of the incidence and survival for intraductal carcinoma of the prostate.
    Dinerman BF; Khani F; Golan R; Bernstein AN; Cosiano MF; Margolis DJ; Hu JC
    Urol Oncol; 2017 Dec; 35(12):673.e9-673.e14. PubMed ID: 28919182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
    Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
    Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.
    Chen X; Yang Y; Wang W; Han B; Qi M; Geng S; Xu J; Zhang Q; Wang X; Chen S; Shi K; Ke X; Zhang J
    Pathol Res Pract; 2020 Jan; 216(1):152693. PubMed ID: 31734052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Distribution of intraductal carcinoma of the prostate and associated lesions in the cancer foci on radical prostatectomy specimens].
    Sakamoto N; Maki T; Kobayashi S; Kobayashi T; Hamaguchi M; Yoshikawa M; Iguchi A; Momosaki S; Nakayama Y
    Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):163-70; discussion 171. PubMed ID: 25757345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Akamatsu S; Terada N; Miyazawa Y; Narita S; Haba R; Sugimoto M
    Jpn J Clin Oncol; 2023 Oct; 53(10):984-990. PubMed ID: 37496400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.
    Rijstenberg LL; Hansum T; Hollemans E; Kweldam CF; Kümmerlin IP; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJLH
    Histopathology; 2020 Nov; 77(5):742-748. PubMed ID: 32542746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rising incidence of ductal adenocarcinoma and intraductal carcinoma of the prostate: Diagnostic accuracy of biopsy, MRI-visibility, and outcomes.
    Pahouja G; Patel HD; Desai S; Rac G; Cheng T; Okabe Y; Gorbonos A; Quek ML; Flanigan RC; Picken MM; Gupta GN
    Urol Oncol; 2023 Jan; 41(1):48.e11-48.e18. PubMed ID: 36441068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    Ericson KJ; Wu SS; Lundy SD; Thomas LJ; Klein EA; McKenney JK
    J Urol; 2020 Feb; 203(2):311-319. PubMed ID: 31483693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
    Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
    Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
    [No Abstract]   [Full Text] [Related]  

  • 38. Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.
    Tonttila PP; Ahtikoski A; Kuisma M; Pääkkö E; Hirvikoski P; Vaarala MH
    BJU Int; 2019 Dec; 124(6):992-998. PubMed ID: 31102571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.